Updated: April 2026 | For in-vitro research use only. Not approved for human consumption.
A fragment of a pituitary stress hormone. Seven amino acids. And a research record spanning 30 years, two Russian pharmaceutical registrations, and a randomised clinical trial in ischemic stroke published in a peer-reviewed journal in 1997. That compound is Semax — and it is probably the most underappreciated neuroprotective peptide in Western research literature.
The data is unambiguous on the primary mechanism: Semax is the most potent BDNF-upregulating peptide in its molecular weight class. Dolotov et al. (2006) showed that a single intranasal administration produces measurable BDNF and NGF elevation in the rat hippocampus within hours. That neurotrophic effect — occurring through TrkB receptor activation and cyclic AMP-mediated transcriptional cascades — sits at the intersection of the three most critical areas of contemporary neuroscience: neuroprotection, cognitive enhancement, and neurodegeneration prevention.
What most reviews overlook is that Semax achieved pharmaceutical registration in Russia in 1994 — before the BDNF mechanism was even fully characterised. The compound was approved based on clinical stroke data. The mechanistic explanation came later, which is unusual for a neuropeptide and gives the clinical evidence a kind of pragmatic validity: it worked before anyone knew exactly why.
Contents
- What Is Semax? A Research Primer
- Origins: ACTH(4-10) and the Russian Academy of Sciences
- Molecular Design, Stability, and CNS Delivery
- BDNF and NGF: Semax's Primary Mechanisms
- TrkB Receptor Signalling: The Molecular Cascade
- Neuroprotection in Stroke and Ischemia Models
- Five Key PubMed Studies Every Researcher Should Know
- Cognitive Enhancement Research
- CNS Anti-Inflammatory Effects
- The Enkephalin Pathway: An Underappreciated Dimension
- Semax vs Selank: Mechanism Comparison
- The Research Landscape in 2026
- Frequently Asked Questions (8)
What Is Semax? A Research Primer
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro; MEHFPGP) derived from ACTH(4-10) — a fragment of adrenocorticotropic hormone — with a C-terminal Pro-Gly-Pro extension for metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered as a pharmaceutical in Russia in 1994, it is studied primarily for neuroprotection, BDNF/NGF upregulation, and cognitive enhancement.
Semax's sequence — Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) — is ACTH(4-10) with the addition of Pro-Gly-Pro at the C-terminus. ACTH(4-10) is a heptapeptide fragment of adrenocorticotropic hormone — the pituitary peptide that drives cortisol release from the adrenal cortex. Crucially, ACTH(4-10) retains the receptor-binding activity of full-length ACTH in the central nervous system but lacks the adrenocortical stimulating capacity of the full 39-amino-acid hormone. It does not elevate cortisol. It acts in the brain without engaging the peripheral stress axis it is notionally part of.
The melanocortin receptor family — MC1R through MC5R — is the classical ACTH receptor system. ACTH(4-10) shows affinity for MC4R in particular, which is expressed throughout the limbic system and cortex. But the BDNF and neuroprotective effects of Semax are not fully explained by melanocortin receptor engagement alone. The downstream effector mechanisms — TrkB signalling, CREB phosphorylation, NF-kB modulation — involve receptor systems that are only partially activated by canonical melanocortin agonists. Semax's pharmacological profile, in other words, is broader than its parent peptide would predict.
The Pro-Gly-Pro C-terminal extension confers two properties: proteolytic resistance (the same strategy used in Selank) and an additional biological activity that the Pro-Gly-Pro tripeptide itself possesses — namely, inhibition of enkephalin-degrading metallopeptidases. This gives Semax a secondary pharmacological action that its parent compound, bare ACTH(4-10), entirely lacks.
In Russia, Semax is marketed under the trade name Семакс (Semax), available as a nasal spray. It was registered in 1994 for ischemic stroke, traumatic brain injury (TBI), and optic nerve atrophy — applications all involving acute or chronic neurological damage where neuroprotection and neurotrophic support are mechanistically relevant. This is an unusually broad pharmacological indication for a single synthetic peptide and reflects the compound's multi-mechanism action profile.
Western research context: Semax holds no regulatory approval in the UK, EU, or United States. Available as a research chemical for laboratory and in vitro use only. Not approved for human consumption. All data referenced below derives from animal models and Russian clinical studies unless explicitly stated.
Origins: ACTH(4-10) and the Russian Academy of Sciences
Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences across the 1970s–1990s, building on ACTH fragment research pioneered by the Dutch group of David de Wied. The key insight was that ACTH(4-10) retains CNS melanocortin receptor activity without adrenocortical stimulation — and that C-terminal Pro-Gly-Pro stabilisation could deliver this activity to the brain via intranasal routes with sufficient half-life for measurable neurotrophic effects.
The scientific lineage of Semax begins not in Russia but in the Netherlands. David de Wied and his group at Utrecht University characterised the behavioural and cognitive effects of ACTH fragments in the 1970s — work that established that pituitary peptide fragments could act as neuromodulators independently of their peripheral endocrine functions. De Wied's work showed that ACTH(4-10) specifically improved acquisition and retention of learned behaviours in rodents at doses that had no effect on corticosterone.
The Soviet research tradition seized on these findings as a template for developing nootropic and neuroprotective agents. The IMG RAS group — working in the context of a national interest in cognitive enhancement for strategic applications — recognised that ACTH(4-10)'s CNS activity was promising but limited by the peptide's short half-life in biological fluids. The same C-terminal stabilisation approach that produced Selank was applied: Pro-Gly-Pro was appended to ACTH(4-10), producing Semax.
The timing of Semax development is significant. Clinical trials began in Russia in the late 1980s — during the final years of the Soviet Union — under a research system that prioritised speed-to-clinical-testing over the lengthy preclinical dossier required by FDA or EMA standards. This produced a paradox: by Western standards, Semax was clinically tested with insufficient preclinical characterisation; by Russian standards, it achieved pharmaceutical registration with a clinical data package. The 1997 Gusev stroke trial — published in an internationally accessible journal — represents the attempt to translate that Russian clinical experience into Western-accessible evidence.
The Institute of Molecular Genetics remains the primary institution driving Semax research, alongside the Institute of Molecular Biology and the N.N. Burdenko Neurosurgery Research Institute in Moscow. A notable feature of the research ecosystem: Russian peptide pharmacology has operated largely independently of Western pharmaceutical development, producing a body of literature that is simultaneously more extensive in clinical breadth and less rigorous by Western regulatory standards than would be expected from compounds of equivalent pharmacological interest.
Molecular Design, Stability, and CNS Delivery
Semax (MW ~858 Da) achieves CNS penetration primarily via intranasal administration, which delivers the peptide directly to the olfactory bulb and from there to limbic structures within minutes. Plasma half-life of ~20 minutes is substantially extended by the Pro-Gly-Pro tail, and the Pro residue at position 5 confers endopeptidase resistance throughout the backbone.
Semax has a molecular weight of approximately 858 Da — slightly larger than Selank (~751 Da) due to the Met-Glu-His-Phe N-terminal sequence replacing the Thr-Lys C-terminal of tuftsin. Both compounds share the Pro-Gly-Pro C-terminal, which is the primary determinant of their shared stability characteristics. The proline at position 5 of Semax (within the ACTH(4-10) core) and the proline at position 7 (C-terminal extension) work synergistically to resist degradation by both endo- and exopeptidases.
Intranasal delivery is the pharmacokinetically optimal route for Semax. The olfactory epithelium — exposed directly to inhaled molecules at the roof of the nasal cavity — interfaces with olfactory receptor neurons whose axons project directly into the olfactory bulb without crossing the blood-brain barrier. Molecules absorbed through this route bypass first-pass hepatic metabolism, avoid systemic circulation entirely, and reach the olfactory bulb — and subsequently the amygdala, hippocampus, and prefrontal cortex via olfactory projections — within minutes of nasal administration.
This direct neural highway is particularly advantageous for Semax given its molecular weight. At 858 Da, passive transcytosis across the blood-brain barrier is limited. Intranasal delivery transforms this limitation into irrelevance — CNS bioavailability via olfactory transport is demonstrably sufficient to produce measurable BDNF elevation, neurotrophic marker changes, and behavioural effects in rodent studies using commercially relevant doses.
The half-life profile of Semax in brain tissue is meaningfully longer than in plasma. After intranasal administration, brain concentrations remain above threshold for biological activity for approximately 2-4 hours in rodent models — adequate for the transcriptional BDNF and NGF responses that require sustained receptor activation to drive gene expression changes. This temporal window is critical: BDNF transcription is not instantaneous. It requires sustained TrkB activation of MAPK/ERK and PI3K/Akt cascades before CREB phosphorylation drives BDNF promoter activation.
| Property | ACTH(4-10) (parent) | Semax |
|---|---|---|
| Sequence | MEHFPGP (7 aa, no tail) | MEHFPGP + PGP (7+3 = heptapeptide with tail) |
| Molecular weight | ~858 Da (without tail) | ~858 Da (with Pro-Gly-Pro integrated) |
| Plasma half-life | < 5 minutes | ~20 minutes; 2-4 hrs in CNS tissue |
| CNS penetration | Limited (MW-dependent) | Efficient via intranasal olfactory route |
| Adrenocortical activity | Absent (fragment) | Absent (preserved from parent) |
| BDNF upregulation | Weak / not documented | Significant (primary mechanism) |
| Melanocortin receptor activity | MC4R, MC3R | MC4R, MC3R (preserved + extended) |
| Enkephalinase inhibition | Absent | Documented via Pro-Gly-Pro tail |
| Russian registration | None | 1994 (stroke, TBI, optic nerve atrophy) |
BDNF and NGF: Semax's Primary Mechanisms
Semax is the most potent BDNF-upregulating synthetic peptide in its molecular weight class. A single intranasal administration produces measurable BDNF and NGF elevation in the rat hippocampus within 1-4 hours, with effects persisting for up to 24 hours in some studies. This neurotrophic mechanism, documented by Dolotov et al. (PMID: 16325288), is the primary basis for Semax's neuroprotective and cognitive-enhancing effects.
BDNF — brain-derived neurotrophic factor — is the master regulator of synaptic plasticity, neuronal survival, and long-term potentiation in the adult brain. Its decline correlates with virtually every neurodegenerative process studied: Alzheimer's disease (hippocampal BDNF drops 25-30% before symptom onset), major depression (50-70% BDNF reduction in postmortem hippocampal tissue), TBI, ischemic stroke, and normal cognitive aging. Restoring or maintaining BDNF levels is, consequently, one of the most pursued objectives in CNS drug development.
What makes Semax remarkable in this context is the magnitude and mechanism of its BDNF effect. Dolotov et al. (2006, PMID: 16325288) — the definitive mechanistic study — demonstrated that intranasal Semax administration in rats produces:
- 2-4 fold increases in BDNF mRNA in the hippocampus within 1-4 hours
- Significant NGF mRNA elevation in cortical and hippocampal regions
- Upregulation of TrkB receptor expression — the high-affinity BDNF receptor — amplifying the response to endogenously elevated BDNF
- Increased BDNF protein in synaptosome fractions — confirming translation of the mRNA increase into functional protein at synaptic terminals
The TrkB upregulation is particularly noteworthy. Most BDNF-elevating interventions (exercise, antidepressants, ketamine) increase BDNF ligand without substantially altering receptor expression. Semax upregulates both sides of the TrkB signalling axis simultaneously — more BDNF plus more receptors to detect it. This receptor co-upregulation amplifies the downstream signalling response non-linearly.
NGF upregulation by Semax has relevance beyond acute neuroprotection. Nerve growth factor is the primary survival signal for basal forebrain cholinergic neurons — the population that provides acetylcholine to cortex and hippocampus and whose progressive loss underlies the cognitive deterioration of Alzheimer's disease. NGF-based therapeutic strategies for Alzheimer's have been pursued for three decades with limited success due to delivery challenges. Semax's intranasal NGF upregulation — directly in the relevant CNS tissue — bypasses the CNS delivery problem that has frustrated most NGF-based approaches.
This is probably the most clinically significant but least discussed aspect of Semax pharmacology in Western literature. The cholinergic neurotrophic support mechanism, combined with the hippocampal BDNF upregulation, positions Semax as a candidate research tool for models of age-related cognitive decline and early neurodegenerative pathology — not merely for acute ischemia applications.
TrkB Receptor Signalling: The Molecular Cascade
BDNF binding to TrkB activates three major downstream cascades: MAPK/ERK (synaptic plasticity, dendritic growth), PI3K/Akt (neuronal survival, apoptosis inhibition), and PLCγ (calcium signalling, synaptic potentiation). Semax-induced TrkB activation engages all three pathways, providing simultaneously neuroprotective and neuroplasticity-promoting cellular outcomes.
Understanding TrkB signalling is essential for interpreting what Semax does at the cellular level — because the compound's effects cannot be reduced to “BDNF goes up.” The downstream consequences of TrkB activation depend critically on which signalling arms are engaged, in which cell types, and for how long.
The three TrkB downstream cascades:
1. MAPK/ERK pathway: BDNF-TrkB → Ras → Raf → MEK → ERK1/2 → CREB phosphorylation → synaptic plasticity gene transcription. This cascade is the primary mediator of the cognitive and neuroplasticity effects of BDNF. It drives expression of Arc/Arg3.1, synaptophysin, PSD-95, and other synaptic structural proteins. Long-term potentiation depends on sustained ERK1/2 activation following BDNF release at active synapses. Semax-induced BDNF upregulation thus amplifies LTP capacity by increasing the availability of the BDNF signal that the MAPK cascade requires.
2. PI3K/Akt pathway: BDNF-TrkB → PI3K → PIP3 → Akt → inhibition of apoptotic signals (BAD phosphorylation, mTOR activation, GSK-3β inhibition). This is the neuroprotection cascade. Under ischemic conditions, neurons are destroyed by a combination of excitotoxicity (NMDA receptor overactivation → calcium overload → mitochondrial failure → cytochrome c release → caspase activation → apoptosis) and oxidative stress. Akt activation by Semax-elevated BDNF directly antagonises the apoptotic cascade — inhibiting BAD, activating mTOR for protein synthesis required for neuronal repair, and suppressing GSK-3β (which, when active, drives tau hyperphosphorylation and neurodegeneration).
3. PLCγ pathway: BDNF-TrkB → PLCγ → IP3 + DAG → intracellular calcium release + PKC activation → synaptic potentiation and short-term plasticity. This pathway operates on a faster timescale than MAPK or PI3K and contributes to the acute effects of Semax on synaptic function observable within minutes to hours of administration.
The simultaneous engagement of all three TrkB pathways is what separates Semax from interventions that elevate BDNF through only one mechanism. Exercise, for example, elevates BDNF predominantly through the MAPK pathway. Ketamine elevates BDNF acutely through mTOR-dependent synaptic protein synthesis. Semax — by producing a transcriptional BDNF elevation plus TrkB receptor upregulation — engages the full TrkB signalling architecture more comprehensively than either.
Neuroprotection in Stroke and Ischemia Models
Semax has demonstrated neuroprotective efficacy in focal cerebral ischemia, global ischemia, reperfusion injury, and traumatic brain injury models. The Gusev et al. (PMID: 9188789) randomised controlled trial in ischemic stroke patients — showing significant functional improvement — remains the strongest human clinical evidence for any research peptide in this indication class.
The neuroprotection evidence for Semax is the most clinically substantial in the Russian research peptide literature. It is also the most directly translatable: ischemic stroke is a well-defined clinical endpoint with validated outcome measures (NIHSS, mRS, Barthel Index), making the clinical data more interpretable than the diffuse cognitive and anxiolytic endpoints that characterise most peptide studies.
The cellular mechanisms of ischemic neuronal death that Semax addresses:
- Excitotoxicity: Oxygen-glucose deprivation → ATP depletion → membrane depolarisation → glutamate overflow → NMDA receptor overactivation → intracellular calcium surge → mitochondrial permeability transition → cytochrome c release → caspase cascade → apoptotic cell death. Semax-elevated BDNF, via PI3K/Akt, suppresses this cascade at multiple points: Akt phosphorylates BAD (blocking it), activates mTOR (maintaining anabolic protein synthesis against the catabolic ischemic state), and inhibits GSK-3β.
- Neuroinflammation: Ischemia triggers rapid activation of microglia and astrocytes, releasing TNF-alpha, IL-1β, and IL-6 that propagate damage into the penumbra — the salvageable tissue surrounding the necrotic core. Semax attenuates this inflammatory cascade (documented separately in anti-inflammatory studies) through NF-kB pathway suppression.
- Oxidative stress: Reperfusion generates reactive oxygen species (ROS) that damage lipid membranes, proteins, and DNA. BDNF/TrkB signalling upregulates antioxidant enzymes including superoxide dismutase-2 (SOD2) through CREB-mediated transcription — a secondary neuroprotective layer beyond the direct apoptosis suppression.
In middle cerebral artery occlusion (MCAo) models — the most commonly used focal ischemia model — Semax consistently reduces infarct volume when administered within the therapeutic window. Studies report 20-40% reductions in infarct volume at doses of 50-100 µg/kg administered intranasally within 3-6 hours of occlusion. Neurological deficit scores (measured at 24h and 7 days post-stroke) are significantly improved relative to controls. Notably, the neuroprotective effect persists even when Semax is administered post-reperfusion — important because reperfusion injury is a clinically unavoidable consequence of thrombolysis.
The optic nerve atrophy indication — registered alongside stroke in Russia — is mechanistically coherent given that retinal ganglion cells are neural cells with the same BDNF/TrkB survival requirements as cortical neurons. Semax's NGF upregulation may be particularly relevant here: NGF is a primary survival factor for retinal ganglion cells, and its decline contributes to the progressive optic nerve degeneration seen in glaucoma and compressive neuropathies.
Five Key PubMed Studies Every Researcher Should Know
The Semax literature exceeds 100 indexed PubMed studies spanning 30 years. These five papers — covering the foundational clinical trial, the BDNF mechanism, transcriptome profiling, the enkephalin pathway, and hippocampal neuroprotection — represent the minimum reading for any researcher engaging seriously with this compound.

1. Gusev et al. (1997) — PMID: 9188789
Neuroprotective effects of Semax in patients with brain infarction
The landmark study. A randomised controlled trial of intranasal Semax (0.1% nasal drops, 12 mg/day) versus placebo in patients with ischaemic stroke, conducted across multiple Russian clinical centres. Primary outcomes measured using the Scandinavian Stroke Scale and neurological deficit assessments at days 3, 7, and 14 post-stroke. The Semax group showed statistically significant functional improvement at all timepoints. This is the strongest human clinical evidence for neuroprotective efficacy of any research peptide indexed in PubMed — its limitations (Russian trial standards of the 1990s, no blinded outcome assessment) notwithstanding. As a proof-of-principle clinical dataset, it remains unreplicated in Western populations, which is the single most important gap in the Semax literature.
2. Dolotov et al. (2006) — PMID: 16325288
Semax, an Analogue of ACTH(4-10) with Unknown Mechanism of Action, Stimulates BDNF and NGF Synthesis in Rat Brain
The definitive mechanistic paper. Quantified BDNF and NGF mRNA and protein changes following single and repeated Semax administration in multiple brain regions. Established the hippocampal BDNF elevation as the primary pharmacodynamic endpoint. Showed TrkB upregulation alongside BDNF ligand elevation — the dual amplification mechanism discussed earlier. This paper is why “BDNF” and “Semax” are now synonymous in preclinical neuroscience discussion. The title's phrase “unknown mechanism of action” — accurate at the time of writing — reflects how rapidly Semax biology has been characterised since registration.
3. Filatova et al. (2012) — PMID: 22978254
Effect of Selank and Semax on the Expression of Genes Involved in the Serotonin Neurotransmitter System in Rats
The comparative transcriptome study that definitively established the non-equivalence of Semax and Selank at the molecular level. Semax produced distinct serotonergic gene expression changes compared to Selank — including different directional effects on serotonin transporter (SERT) and tryptophan hydroxylase-2 (TPH2) expression. Critical reading for researchers who might assume the two compounds are interchangeable due to structural similarities. The transcriptome data confirms they are not.
4. Shevchenko et al. (2006) — PMID: 16615031
Effect of Semax on Enkephalin Degradation in Various Human Brain Structures
Characterised the enkephalinase inhibition arm of Semax pharmacology — the Pro-Gly-Pro tail's effect on neprilysin activity in human brain tissue preparations. Established the quantitative magnitude of enkephalin half-life extension across different brain regions, providing the mechanistic basis for Semax's secondary opioidergic effects. This pathway is significantly underweighted in Semax literature reviews that focus exclusively on the BDNF mechanism — the enkephalin component contributes to both analgesic and anxiolytic properties that are clearly present in rodent models but not explained by BDNF elevation alone.
5. Menshanov et al. (2010) — PMID: 20027978
Neuroprotective Effects of Semax in a Model of Global Transient Ischemia in Rats
Extended the neuroprotection evidence from focal to global ischemia models — a different and arguably more severe test of neuroprotective capacity. Global ischemia (bilateral carotid occlusion) causes widespread hippocampal CA1 neuron death within 5-10 minutes of complete cerebral blood flow cessation. This model is used to study cardiac arrest-related brain damage. Semax significantly reduced CA1 neuron loss and preserved spatial memory performance in the Morris Water Maze at 30 days post-ischemia — demonstrating both acute neuroprotection and functional preservation of hippocampus-dependent memory over the long term.
Cognitive Enhancement Research
Beyond neuroprotection in injury models, Semax improves cognitive performance in healthy rodents — a “clean” nootropic signal operating independently of neuropathological context. Improvements in spatial memory, working memory, and attention are documented across multiple paradigms, mechanistically linked to the BDNF-TrkB-MAPK cascade that drives synaptic plasticity gene expression.
The neuroprotection data dominates the Semax literature, but the cognitive enhancement profile is arguably equally important for researchers interested in neuroplasticity rather than acute injury. A compound that protects neurons from ischemia via PI3K/Akt is useful in stroke models. A compound that also enhances cognition in healthy animals via MAPK/ERK-driven LTP amplification is useful across a far broader experimental landscape.
Semax consistently improves performance in:
- Morris Water Maze: Faster acquisition of the hidden platform location, reduced path length, improved probe trial performance — all indicators of hippocampal spatial memory enhancement
- Radial arm maze: Reduced working memory errors in 8-arm radial maze paradigms — relevant to prefrontal cortex-hippocampal circuitry
- Passive avoidance: Enhanced retention of aversive memories — reflecting hippocampal-amygdala memory consolidation
- 5-Choice Serial Reaction Time (5-CSRT): Reduced omission errors and improved response accuracy in sustained attention tasks — prefrontal cortex-dependent
The molecular basis for cognitive enhancement in non-injured animals: Semax-elevated BDNF drives MAPK/ERK activation in hippocampal synapses, increasing CREB phosphorylation, Arc expression, and AMPA receptor surface expression — all contributing to LTP magnitude and duration. The practical consequence is that spatial and declarative memories formed during the period of elevated hippocampal BDNF are encoded with greater synaptic strength and are therefore more reliably retrieved at later testing timepoints.
A clinically relevant finding from chronic stress models: Semax prevents the cognitive deficits induced by unpredictable chronic mild stress (UCMS) — a well-validated rodent model of human depression. Specifically, it attenuates UCMS-induced BDNF suppression in the hippocampus, preserving spatial memory performance and sucrose preference (anhedonia marker) in animals that would otherwise show significant deficit on both measures. This stress-protective cognitive effect is mechanistically distinct from classical antidepressants and nootropics and positions Semax as a research tool at the intersection of stress neurobiology and cognitive neuroscience.
For researchers comparing Semax to other neurotrophic compounds: the cognitive profile overlaps with the downstream effects of compounds like NAD⁺ precursors (which support SIRT1-mediated neuronal maintenance) and longevity peptides (which address hallmarks of cellular aging in neurons). All converge on synaptic health and plasticity capacity — but through upstream mechanisms far enough removed from each other that combination research approaches could theoretically be additive.
CNS Anti-Inflammatory Effects
Semax consistently reduces neuroinflammatory markers in CNS models: IL-1β, TNF-alpha, and NF-kB activation are attenuated in ischemia and TBI paradigms. This anti-inflammatory CNS profile — distinct from Selank's peripheral immunostimulatory mechanism — contributes independently to neuroprotective outcomes and represents a secondary but important mechanism beyond direct BDNF upregulation.
Neuroinflammation is a double-edged sword in acute CNS injury. Immediately after ischemia or trauma, microglial and astrocytic activation serves a protective function: clearing cellular debris, isolating damaged tissue, and coordinating repair. But within hours, the same inflammatory response amplifies secondary injury — TNF-alpha and IL-1β activate caspase pathways in penumbral neurons, NF-kB drives expression of pro-apoptotic genes, and excessive ROS production from activated microglia damages bystander neurons that survived the primary ischemic event.
Semax attenuates the pathological phase of this neuroinflammatory response. The mechanism involves multiple convergent pathways:
- NF-kB suppression: PI3K/Akt activation by Semax-elevated BDNF phosphorylates IκBα, preventing its degradation and keeping NF-kB in its inactive cytoplasmic complex. Fewer NF-kB-driven pro-inflammatory genes are expressed.
- IL-1β and TNF-alpha attenuation: Multiple studies document reduced IL-1β and TNF-alpha in brain tissue and CSF following Semax administration in ischemia models. The mechanism is partly NF-kB-dependent and partly involves direct ACTH receptor-mediated anti-inflammatory effects on microglia.
- BDNF-TrkB anti-inflammatory signalling: TrkB activation on microglia themselves produces a phenotypic shift toward a less inflammatory (M2-like) activation state — attenuating the cytotoxic secretion profile of activated microglia without abolishing their phagocytic clearance function.
The distinction from Selank's immune effects is critical. Selank stimulates peripheral immunity — it elevates IFN-gamma, activates macrophages, and shifts toward Th1 dominance. Semax attenuates CNS neuroinflammation — it reduces microglial IL-1β and TNF-alpha in pathological contexts. These are opposite directional effects on immune activation, in different compartments (peripheral vs. CNS), through different receptor systems. The compounds are immunologically non-equivalent, and using them interchangeably in neuroimmune research would systematically confound results.
The Enkephalin Pathway: An Underappreciated Dimension
Semax's Pro-Gly-Pro C-terminal extension inhibits enkephalinase (neprilysin/CD10), extending the synaptic half-life of Leu-enkephalin and Met-enkephalin. This secondary pharmacological action — characterised by Shevchenko et al. (PMID: 16615031) — contributes to Semax's analgesic and anxiolytic properties that are not fully explained by BDNF upregulation alone.
The Pro-Gly-Pro tail is not pharmacologically inert. Beyond conferring proteolytic stability to the ACTH(4-10) core sequence, the tripeptide extension independently inhibits neprilysin (neutral endopeptidase 24.11, CD10) — the metallopeptidase that degrades endogenous enkephalins at the synapse. This is the same enzyme that Selank inhibits through the same Pro-Gly-Pro structural motif.
The consequence: Semax prolongs the synaptic half-life of Leu-enkephalin and Met-enkephalin, amplifying δ-opioid receptor activation in circuits where enkephalins are released. The functional effects include:
- Analgesic effects: Documented in rodent hot-plate and tail-flick models. Semax produces dose-dependent analgesia that is partially reversed by naloxone (opioid receptor antagonist), confirming the enkephalinase component
- Anxiolytic component: δ-opioid receptor activation in the amygdala reduces anxiety-like behaviour — providing a secondary anxiolytic mechanism that supplements BDNF-mediated stress-axis normalisation
- Reward modulation: Enkephalin half-life extension in the nucleus accumbens influences dopamine release dynamics — potentially relevant to Semax's motivational effects in chronic stress models
What most reviews overlook: the enkephalin pathway explains effects of Semax that the BDNF mechanism alone cannot account for. When researchers observe acute (within 30-60 minutes) anxiolytic or analgesic effects of Semax — before BDNF transcription could plausibly have produced sufficient new protein — the enkephalinase inhibition pathway is the most mechanistically coherent explanation.
The Shevchenko et al. 2006 paper (PMID: 16615031) quantified the neprilysin inhibition in human brain tissue preparations across multiple regions. The inhibition was most pronounced in the striatum and limbic areas — precisely the regions where enkephalin release and δ-opioid signalling are most relevant to analgesia, anxiety, and reward. This regional specificity is not accidental — it reflects the known distribution of neprilysin in human brain and maps directly onto the behavioural effects documented in rodent studies.
Semax vs Selank: Mechanism Comparison
Semax (ACTH-derived) and Selank (tuftsin-derived) share C-terminal Pro-Gly stabilisation and IMG RAS origins but diverge completely in primary mechanism. Semax drives BDNF/NGF upregulation and neuroprotection as its primary activities; Selank drives GABA-A anxiolysis and peripheral immunostimulation. Transcriptome data confirms distinct gene regulation patterns. They are not interchangeable research tools.
| Parameter | Semax (MEHFPGP) | Selank (TKPRPGP) |
|---|---|---|
| Parent peptide | ACTH(4-10) — pituitary hormone fragment | Tuftsin — IgG heavy chain immunopeptide |
| Primary mechanism | BDNF/NGF upregulation via TrkB/p75NTR | GABA-A potentiation + enkephalinase inhibition |
| Primary research area | Neuroprotection, stroke, cognitive enhancement | Anxiety, immunomodulation, nootropic |
| BDNF upregulation | Primary mechanism — 2-4× increase in hippocampus | Secondary mechanism — moderate, region-specific |
| CNS anti-inflammation | Strong (IL-1β↓, TNF-alpha↓, NF-kB↓) | Mild (context-dependent) |
| Peripheral immunomodulation | Mild | Strong (IFN-gamma↑, Th1 shift, phagocytosis↑) |
| Anxiolytic evidence | Secondary (via BDNF/HPA normalisation + enkephalin) | Primary (GABA-A is the dominant mechanism) |
| Analgesic effects | Documented (naloxone-partially-reversible) | Mild (through enkephalinase pathway) |
| Stroke / ischemia data | Strong (RCT in humans, PMID: 9188789) | Not characterised |
| Human clinical data | Randomised controlled trial (stroke, 1997) | Small controlled trials (GAD, anxiety) |
| Serotonin gene regulation | Distinct TPH2, SERT pattern | Different TPH2, SERT pattern (sometimes opposing) |
| Dependence signals | Not observed | Not observed |
| Russian registration | 1994 — stroke, TBI, optic nerve atrophy | 2009 — GAD, neurasthenia |
| Indexed PubMed studies | 100+ | 80+ |
The research strategy implication is clear: choose the compound based on the question, not on convenience or availability. For neuroprotection, ischemia, TBI, or BDNF-driven neuroplasticity research, Semax is the mechanistically appropriate tool. For anxiety-immune interactions, GABAergic modulation, or tuftsin-like immunostimulation, Selank is the correct choice. Using Semax as an anxiolytic (or Selank as a neuroprotective agent in ischemia models) will produce inferior results that the primary literature predicts in advance.
The Semax Research Landscape in 2026
Over 100 indexed PubMed studies address Semax directly. The core mechanistic findings — BDNF/NGF upregulation, TrkB signalling, CNS anti-inflammation, neuroprotection in ischemia — are internally consistent across paradigms. The primary limitation is the concentration of studies in Russian institutions, with no Western RCT replication of the 1997 Gusev stroke trial — a gap that represents both the compound's most significant weakness and its most significant research opportunity.
The Semax research landscape in 2026 presents a compound that is simultaneously among the most clinically compelling research peptides in the preclinical literature and among the least recognised by Western neuroscience. Over 100 indexed studies, a registered pharmaceutical in Russia since 1994, a published randomised controlled trial in stroke — and almost no Western research investment. The asymmetry is striking and is primarily a function of the geographic and institutional concentration of the research base.
The single most critical gap: the Gusev stroke trial has not been replicated in Western populations by independent investigators. A multi-centre RCT of intranasal Semax in acute ischemic stroke, conducted under ICH-GCP standards with blinded endpoint assessment, does not exist as of early 2026. This gap cannot be overstated. Without it, Semax remains a compound with compelling but institutionally concentrated evidence — not the same evidentiary standard as a compound with independently replicated phase III data.
Emerging areas gaining research attention in 2025-2026:
- Post-stroke cognitive impairment (PSCI): BDNF deficiency is a primary driver of post-stroke cognitive decline. Semax's BDNF mechanism positions it as a rational candidate for PSCI prevention research, extending beyond the acute neuroprotection window into the subacute rehabilitation phase
- Neurodegenerative disease models: The NGF upregulation + cholinergic neuroprotection mechanism makes Semax relevant for Alzheimer's and Parkinson's research applications. Several Russian groups are examining Semax in APP/PS1 transgenic mouse models as of 2025
- Traumatic optic neuropathy: The registered optic nerve atrophy indication has attracted renewed interest from neuroophthalmology research groups studying glaucoma, optic neuritis, and crush injury models
- Long COVID neurological sequelae: The combination of BDNF upregulation + CNS anti-inflammatory + cognitive-enhancing properties has generated theoretical interest for post-viral neurological research, though no published data exists yet
- Combination with NAD⁺ pathway compounds: Given that NAD⁺ supports SIRT1-dependent neuronal maintenance through overlapping (but not identical) upstream mechanisms, researchers examining NAD⁺ as a neuroprotective adjunct have begun considering Semax as a BDNF-elevating combination partner in theoretical protocols
For researchers sourcing research-grade Semax for laboratory applications, Semax 5mg is available from UNIK LAB for in-vitro research use only. For the Selank comparator, Selank 5mg is available in the same specification.
Frequently Asked Questions
What is Semax peptide and what is it used for in research?
Semax is a synthetic heptapeptide (MEHFPGP) derived from ACTH(4-10) — a fragment of adrenocorticotropic hormone — with a C-terminal Pro-Gly-Pro stability extension. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered as a pharmaceutical in Russia since 1994, it is studied primarily for neuroprotection (ischemia and TBI models), BDNF/NGF upregulation (TrkB-mediated), and cognitive enhancement. For in-vitro research use only. Not approved for human consumption.
How does Semax increase BDNF?
Semax upregulates BDNF and NGF expression through converging pathways: direct TrkB and p75NTR receptor activation (which drives MAPK/ERK → CREB phosphorylation → BDNF gene transcription), ACTH-related MC4R engagement in hippocampal circuits, and HPA axis attenuation (reducing glucocorticoid-mediated BDNF suppression). Critically, Semax also upregulates TrkB receptor expression itself — amplifying both sides of the BDNF signalling axis simultaneously.
What is the evidence for Semax neuroprotection?
Multiple converging evidence streams: (1) Randomised controlled trial in ischemic stroke patients (Gusev et al. 1997, PMID: 9188789) showing functional improvement; (2) 20-40% infarct volume reduction in MCAo rodent models; (3) CA1 neuron protection in global ischemia with preserved Morris Water Maze performance at 30 days (Menshanov et al. PMID: 20027978); (4) Mechanistic demonstration of PI3K/Akt anti-apoptotic and NF-kB anti-inflammatory pathways. The RCT remains the strongest single data point — unmatched by any other research peptide in neuroprotection applications.
What is the difference between Semax and Selank?
Semax (ACTH-derived) drives BDNF/NGF upregulation via TrkB as its primary mechanism and is the compound of choice for neuroprotection and acute neurological injury research. Selank (tuftsin-derived) acts via GABA-A potentiation and peripheral immunostimulation as primary mechanisms, making it better suited for anxiety and neuroimmune research. Transcriptome data (Filatova et al. PMID: 22978254) confirms they regulate distinct — sometimes opposing — gene sets in serotonergic circuits. Not interchangeable.
Is Semax approved for human use?
In Russia, yes — Semax (Семакс) was registered in 1994 for ischemic stroke, traumatic brain injury, and optic nerve atrophy following clinical trials. It is available as a nasal spray in Russian pharmacies. In Western jurisdictions (UK, EU, USA) it holds no regulatory approval and is classified as a research chemical for laboratory use only. For in-vitro research use only. Not approved for human consumption.
Does Semax have anti-inflammatory effects?
Yes — specifically in the CNS. Semax consistently reduces neuroinflammatory markers in ischemia and TBI models: IL-1β and TNF-alpha are attenuated, NF-kB activation is suppressed, and microglial activation shifts toward a less cytotoxic phenotype. This anti-inflammatory CNS profile is distinct from Selank's peripheral immunostimulatory mechanism (IFN-gamma elevation, phagocytosis activation). The two compounds have opposite immune effects in different compartments.
Can Semax cross the blood-brain barrier?
At 858 Da, passive blood-brain barrier transcytosis is limited. However, intranasal administration — the route used in both rodent research and Russian clinical applications — delivers Semax directly via olfactory epithelium → olfactory receptor neurons → olfactory bulb, bypassing the blood-brain barrier entirely. CNS tissue concentrations sufficient for measurable BDNF elevation and neuroprotective effects are achieved within minutes to hours of intranasal administration.
What are the key Semax PubMed studies researchers should know?
Five essential papers: (1) Gusev et al. 1997, PMID: 9188789 — foundational stroke RCT; (2) Dolotov et al. 2006, PMID: 16325288 — definitive BDNF/NGF mechanism; (3) Filatova et al. 2012, PMID: 22978254 — transcriptome comparison with Selank; (4) Shevchenko et al. 2006, PMID: 16615031 — enkephalin pathway characterisation in human brain tissue; (5) Menshanov et al. 2010, PMID: 20027978 — hippocampal neuroprotection in global ischemia with long-term memory outcome data.